BRAF and melanoma: A more recent clinical study with 22 BRAF+MEK inhibitor-resistant BRAFV600-mutant melanoma patients revealed that the daily oral dose of 360 mg vorinostat was well-tolerated and showed an overall response rate of 9%, including one complete response.